Switch theme
Sign up to access all valuation multiples
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
2015
116
LTM Revenue $5.4M
LTM EBITDA -$229M
$458M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Praxis Precision Medicines has a last 12-month revenue (LTM) of $5.4M and a last 12-month EBITDA of -$229M.
In the most recent fiscal year, Praxis Precision Medicines achieved revenue of $8.6M and an EBITDA of -$200M.
Praxis Precision Medicines expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Praxis Precision Medicines valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.4M | XXX | $8.6M | XXX | XXX | XXX |
| Gross Profit | $5.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$229M | XXX | -$200M | XXX | XXX | XXX |
| EBITDA Margin | -4229% | XXX | -2336% | XXX | XXX | XXX |
| EBIT | -$238M | XXX | -$200M | XXX | XXX | XXX |
| EBIT Margin | -4393% | XXX | -2340% | XXX | XXX | XXX |
| Net Profit | -$223M | XXX | -$183M | XXX | XXX | XXX |
| Net Margin | -4111% | XXX | -2137% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Praxis Precision Medicines's stock price is $39.
Praxis Precision Medicines has current market cap of $785M, and EV of $458M.
See Praxis Precision Medicines trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $458M | $785M | XXX | XXX | XXX | XXX | $-11.21 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Praxis Precision Medicines has market cap of $785M and EV of $458M.
Praxis Precision Medicines's trades at 53.5x EV/Revenue multiple, and -2.3x EV/EBITDA.
Equity research analysts estimate Praxis Precision Medicines's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Praxis Precision Medicines has a P/E ratio of -3.5x.
See valuation multiples for Praxis Precision Medicines and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $785M | XXX | $785M | XXX | XXX | XXX |
| EV (current) | $458M | XXX | $458M | XXX | XXX | XXX |
| EV/Revenue | 84.5x | XXX | 53.5x | XXX | XXX | XXX |
| EV/EBITDA | -2.0x | XXX | -2.3x | XXX | XXX | XXX |
| EV/EBIT | -1.9x | XXX | -2.3x | XXX | XXX | XXX |
| EV/Gross Profit | 84.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.5x | XXX | -4.3x | XXX | XXX | XXX |
| EV/FCF | -1.0x | XXX | -3.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPraxis Precision Medicines's last 12 month revenue growth is 87%
Praxis Precision Medicines's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.8M for the same period.
Praxis Precision Medicines's rule of 40 is -5059% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Praxis Precision Medicines's rule of X is -4011% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Praxis Precision Medicines and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 87% | XXX | 65% | XXX | XXX | XXX |
| EBITDA Margin | -4229% | XXX | -2336% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -5059% | XXX | -2249% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -4011% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1782% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2440% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Praxis Precision Medicines acquired XXX companies to date.
Last acquisition by Praxis Precision Medicines was XXXXXXXX, XXXXX XXXXX XXXXXX . Praxis Precision Medicines acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Praxis Precision Medicines founded? | Praxis Precision Medicines was founded in 2015. |
| Where is Praxis Precision Medicines headquartered? | Praxis Precision Medicines is headquartered in United States of America. |
| How many employees does Praxis Precision Medicines have? | As of today, Praxis Precision Medicines has 116 employees. |
| Who is the CEO of Praxis Precision Medicines? | Praxis Precision Medicines's CEO is Mr. Marcio Souza. |
| Is Praxis Precision Medicines publicy listed? | Yes, Praxis Precision Medicines is a public company listed on NAS. |
| What is the stock symbol of Praxis Precision Medicines? | Praxis Precision Medicines trades under PRAX ticker. |
| When did Praxis Precision Medicines go public? | Praxis Precision Medicines went public in 2020. |
| Who are competitors of Praxis Precision Medicines? | Similar companies to Praxis Precision Medicines include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Praxis Precision Medicines? | Praxis Precision Medicines's current market cap is $785M |
| What is the current revenue of Praxis Precision Medicines? | Praxis Precision Medicines's last 12 months revenue is $5.4M. |
| What is the current revenue growth of Praxis Precision Medicines? | Praxis Precision Medicines revenue growth (NTM/LTM) is 87%. |
| What is the current EV/Revenue multiple of Praxis Precision Medicines? | Current revenue multiple of Praxis Precision Medicines is 84.5x. |
| Is Praxis Precision Medicines profitable? | Yes, Praxis Precision Medicines is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Praxis Precision Medicines? | Praxis Precision Medicines's last 12 months EBITDA is -$229M. |
| What is Praxis Precision Medicines's EBITDA margin? | Praxis Precision Medicines's last 12 months EBITDA margin is -4229%. |
| What is the current EV/EBITDA multiple of Praxis Precision Medicines? | Current EBITDA multiple of Praxis Precision Medicines is -2.0x. |
| What is the current FCF of Praxis Precision Medicines? | Praxis Precision Medicines's last 12 months FCF is -$439M. |
| What is Praxis Precision Medicines's FCF margin? | Praxis Precision Medicines's last 12 months FCF margin is -8103%. |
| What is the current EV/FCF multiple of Praxis Precision Medicines? | Current FCF multiple of Praxis Precision Medicines is -1.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
